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ABSTRACT 
We investigated the role of measurement of serum and urinary type IV collagen (IV-C) levels 
in monitoring diabetic microangiopathy. Furthermore, we compared these levels in diabetic 
nephropathy and non-diabetic renal disease (NDRD). A one-step sandwich enzyme immunoas-
say was used to measure IV-C levels in 82 diabetic patients, 33 NDRD patients and 20 
healthy non-diabetic control subjects. The diabetic patients were classified into four groups 
according to urinary albumin I creatinine index CACI) (mg/g) and serum creatinine (s-Cr) (mg/ 
dl) : normoalbuminuria (ACl<30), microalbuminuria CACI 30-300), albuminuria CACI >300, 
s-Cr<l.99 mg/dl) and renal insufficiency (s-Cr>l.99 mg/dl). Serum and urinary IV-C levels 
were significantly elevated even in diabetic patients without clinical evidence of microangiopa-
thy compared with control subjects (p<0.05 and p<0.01, respectively). Both levels were signifi-
cantly higher in normoalbuminuric patients than in the control subjects, and in patients with 
microalbuminuria, albuminuria or renal insufficiency than in normoalbuminuric patients, 
with significant differences between these groups (serum and urinary IV-C, both p<0.0001 by 
ANOVA). Urinary IV-C and albumin levels were significantly correlated, even in normo- and 
microalbuminuric patients (r = 0.55, p<0.0001). Serum IV-C in normoalbuminuric patients 
rose significantly as the degree of retinopathy progressed from background to proliferative 
stages (p<0.05). Neither serum nor urinary IV-C levels were influenced by glycemic control. 
Albuminuric diabetic patients (with and without renal insufficiency) had significantly higher 
levels of serum IV-C compared with those in proteinuric NDRD patients (p<0.005), though 
there was no significant difference in the urinary IV-C level. However, the urinary IV-CI albu-
min ratio was significantly higher in albuminuric diabetic patients than in proteinuric NDRD 
patients, even after adjusting for s-Cr and creatinine clearance (p<0.0001). In conclusion, we 
suggest that measured serum and urinary IV-C concentrations may serve as new markers for 
monitoring the development and progression of diabetic microangiopathy, particularly nephro-
pathy. Furthermore, the measurement of serum IV-C concentrations and urinary IV-CI albu-
min ratios in diabetic patients may allow diabetic nephropathy and non-diabetic renal disease 
to be differentiated. 
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Thickening of the capillary basement mem-
branes in various tissues, especially kidney and 
retina, is a prominent finding in both insulin-de-
pendent diabetes mellitus (IDDM) and non-insu-
lin-dependent diabetes mellitus (NIDDM), and is 
considered to be an early event in the pathogene-
sis of diabetic microangiopathy4•25,4B). In diabetic 
nephropathy glomerular basement membrane 
thickening parallels the degree of mesangial ex-
pansion 7,44), Recent biochemical and immunohis-
tochemical studies in diabetic patients as well as 
in experimentally diabetic rats have demon-
strated an imbalance in structural macromolecu-
lar components such as type IV collagen (IV-C), 
laminin and proteoglycans, in thickened glomeru-
lar capillary basement membranes and expanded 
mesangial areas2,i5,24,3i,35,42,49). The predomi-
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nant abnormality in these structures is increased 
accumulation and altered distribution of IV-C, 
which is the major structural component of base-
ment membranes. Similar abnormalities have 
also been reported in thickened renal tubular and 
retinal capillary basement membranes14•15). Ab-
normalities of IV-C metabolism therefore appear 
to be a central event in the development of dia-
betic microangiopathy, particularly nephropathy. 
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Increased IV-C production secondary to the dia-
betic milieu12·17) as well as decreased degrada-
tion secondary to the structural changes induced 
by diabetes30) may both be responsible mecha-
nisms. 
IV-C and its fragments, which seems to be re-
leased into the circulation as a consequence of 
normal basement membrane metabolism, can be 
measured in serum by sandwich enzyme immu-
noassay (EIA) and specific radioimmunoassays 
(RIA), respectively19•32·34). Previous studies have 
demonstrated increased serum levels of the 7S 
domain (7S collagen) and the carboxy-terminal 
domain (NCl) of IV-C in streptozotocin-diabetic 
rats3,lS,SS). These increased levels are thought to 
reflect increased synthesis of basement mem-
brane IV-C throughout the body3·18·38). Further-
more, serum levels of IV-C and its fragment 7S 
collagen were reported to be elevated in diabetic 
patients with microangiopathy2o,33,45). In a re-
cent study, urinary excretion of the NC 1 domain 
of IV-C was found to be increased in IDDM pa-
tients in the early stage of incipient diabetic 
nephropathy and it was proposed that this re-
flected altered diabetic glomerular basement 
membrane metabolism47). For clinical use non-in-
vasive methods of measuring the degree of alter-
ation in the basement membrane metabolism are 
desirable. We postulate that the measurement of 
serum and urinary IV-C levels in diabetic pa-
tients may be useful in assessing alterations in 
the basement membrane IV-C metabolism and 
also for monitoring the development and progres-
sion of diabetic microangiopathy. In the present 
study, we therefore measured serum and urinary 
IV-C by sandwich EIA in diabetic patients with 
and without microangiopathy in order to assess 
its value as a non-invasive marker. 
Progressive accumulation of normal constitu-
ents of extracellular matrix, for example IV-C, la-
minin and fibronectin, occurs in the glomerular 
basement membrane and mesangial matrix in a 
number of non-diabetic renal diseases (NDRD), 
including membranous nephropathy, IgA nephro-
pathy and focal glomerulosclerosis16,23,27,28,45). 
Elevated urinary IV-C concentrations may there-
fore not only indicate diabetic nephropathy, but 
also suggest the presence of NDRD in diabetic 
patients. A recent study demonstrated raised se-
rum and urine levels of the NCl domain of IV-C 
in patients with glomerulonephritis compared 
with those in healthy controls26). Furthermore, in 
diabetic patients it is desirable to ascertain 
whether proteinuria results from diabetic or non-
diabetic renal involvement. In order to evaluate 
whether the determination of serum and urinary 
IV-C levels is helpful in differentiating diabetic 
nephropathy and non-diabetic renal disease, we 
compared these levels in patients with diabetic 
nephropathy and non-diabetic renal disease. 
MATERIALS AND METHODS 
Subjects 
Eighty-two diabetic patients (69 NIDDM and 13 
IDDM; 31 males and 51 females) with a mean 
(±SD) age of 53 ( ± 13) years (range 25-75 years) 
and 33 NDRD patients (16 males and 17 females) 
with a mean (±SD) age of 45 ( ± 17) years (range 
14-70 years) were studied. The study was con-
ducted on an inpatient basis. No patient had clin-
ical evidence of liver dysfunction. Diabetic 
patients with clinical and/or serological signs of 
connective tissue disorders were excluded. 
Twenty healthy non-diabetic subjects [mean 
(±SD) age 55 ( ± 9) years, range 40-69 years] un-
dergoing routine annual medical examinations 
were recruited as a control group. 
The diagnosis of all NDRD was established by 
renal biopsy. In diabetic patients, the known 
duration of diabetes, body mass index (BMI), 
blood pressure (BP) and type of antidiabetic 
treatment were recorded. Glycemic control was 
assessed by HbAlC measurements. Twelve 
NIDDM patients were followed for 8 weeks to 
study the effect of improved glycemic control on 
IV-C levels. The grade of retinopathy was deter-
mined by ophthalmologists using ophthalmoscopy 
and I or fluorescein angiography, and classified as 
without retinopathy or with retinopathy includ-
ing background and proliferative retinopathy. The 
degree of nephropathy was assessed by urinary 
albumin I creatinine index CACI) and serum 
creatinine values. The diabetic patients were di-
vided into four groups according to the degree of 
nephropathy: (1) normoalbuminuria: ACI<30 
mg/g, (2) microalbuminuria: ACI 30-300 mg/g, (3) 
albuminuria: ACI>300 mg/g but serum creatinine 
levekl.99 mg/dl, (4) renal insufficiency: serum 
creatinine level >l.99 mg/dl. The ACI was calcu-
lated as urinary albumin concentration 
(mg/L) I urinary creatinine concentration (g/L)41). 
Blood and urinary samples 
Blood and urine samples for measurement of 
IV-C were collected on the same day. In diabetic 
patients serum IV-C was measured in fasting 
blood samples. Urinary IV-C and albumin were 
measured in 24 hour urine collections. The pa-
tients who were followed for 8 weeks had a total 
of three blood and urine examinations over this 
period (two during their inpatient stay and a fi-
nal measurement in our outpatient-clinic within 
2 weeks of discharge). In these patients, first void 
early morning urine samples were used. 
Serum for IV-C measurement was obtained 
from venous blood after clotting and centrifuging 
blood samples for 15 min at 1,800 xg at 4°C. The 
original whole urine was concentrated 100-fold 
before IV-C measurement, because in most urine 
samples the levels were below the detection limit 
of the assay. Concentration was performed with 
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the use of 150 g/L polyethylene glycol (PEG) -
4000 in 0.2M Tris-HCL, pH 7.6 (containing 6.15 
mM sodium azide), in the presence of 0.5 g/L 
y-globulin, as we described previously1). Serum 
and PEG-concentrated urine samples were stored 
at -70°C until analysis of IV-C. 
Laboratory methods 
IV-C concentration was measured in duplicate 
by a one-step sandwich EIA using the Panassay 
IV-C kit (Fuji Chemical Industries Ltd., Toyama, 
J apan)34). In this assay two distinct monoclonal 
antibodies were used, one (clone 4H12) against 
the 7S domain and the other (clone 1D3) against 
the central triple-helical domain of IV-C molecule. 
Briefly, 50 µl of serum or PEG-concentrated urine 
sample or standard IV-C solution was incubated 
with a polystyrene ball coated with mouse anti-
human IV-C monoclonal antibody (clone 4H12) 
and 300µ1 of Fab' (clone 1D3)-peroxidase (0.8 
mg/L) in 10 mM Na-phosphate buffer, pH 7.0 for 
60 min at room temperature. After stopping the 
immunoreaction with lml of 10 mM Na-phos-
phate buffer, pH 7.0 containing O.lM NaCl, the 
polystyrene ball was washed 5 times with 3ml of 
the same buffer. Subsequently, the polystyrene 
ball was incubated with 300µ1of3,3',5,5'-tetrame-
thylbenzidine (0.134 g/L) and 100µ1 of hydrogen 
peroxide (0.15 g/L) in 100 mM acetate buffer (pH 
5.5) for 30 min at room temperature. The enzyme 
reaction was stopped by adding 1 ml 1.33 N 
sulphuric acid, and the absorbance at 450 nm 
was measured by a double-beam spectophotome-
ter (Model-2000; Hitachi, Tokyo, Japan) to calcu-
late IV-C concentration. IV-C measurement from 
PEG-concentrated urine samples showed good re-
covery (102.6±1.0%) and reproducibility [intra-
and interassay coefficients of variation (CVs) 
5.5 ± 0.7% and 4.3±1.7%, respectively]. The in-
tra- and interassay CVs for serum IV-C were 
3.2 ± 0.5% and 5.0±1.0%, respectively. 
The blood glucose was measured by a glucose 
analyzer and HbAlC by HPLC (Glucose AUTO & 
STATTM and AUTO AlC, respectively; Kyoto Daii-
chi Chemical Co. Ltd., Japan). Serum cholesterol 
and triglyceride were determined enzymatically 
(EA test T-CH0600, Triglyzyme®-600; Eiken 
Chemical Co.Ltd., Tokyo, Japan). Serum and uri-
nary creatinine were measured by an enzymatic 
method using a commercial kit (AR CRE-N; Mi-
zuho Medy, Tosu, Japan). Urinary albumin was 
measured by a latex turbidimetric immunoassay 
using mouse anti-human albumin antiserum-
coated latex (Eiken Chemical Co.Ltd., Tokyo, Ja-
pan) and immunochemistry analyzer (Model 
LA-1000; Analytical instruments, Tokyo, Ja-
pan)22·43). This assay has an intra- and interas-
say CV of 4.2±1.1% and 4.5±0.7% respectively 
at concentrations of 1.1-17.0 mg/L. Before quan-
titation, the urine was screened with a semi-
quantitative test strip (Uristix; Ames Division, 
Miles-Sankyo Co. Ltd., Tokyo, Japan) to indicate 
those samples with excess albumin which re-
quired dilution. 
The molecular size distribution of IV-C in the 
serum and PEG-concentrated urine samples was 
determined by Western blotting of immunoprecip-
itated antigens from these samples. Immuno-
precipitation was carried out using rabbit 
anti-human IV-C polyclonal antibody (Chemicon 
International Inc.; Temecula, CA) and goat anti-
rabbit IgG as primary and secondary antibodies, 
respectively. The immunoprecipitate from the se-
rum, urine and calibrator human placental IV-C 
solution (500 µg/L), together with the high molec-
ular weight calibration kit proteins (Pharmacia 
LKB Biotechnology, U ppsala, Sweden) were then 
subjected to sodium dodecyl sulphate-polyacryl-
amide gel electrophoresis (SDS-PAGE) using a 
SDS-polyacrylamide gel with a concentration gra-
dient of 4-20% (Daiichi Pure Chemicals Co. Ltd., 
Tokyo, Japan). After electrophoresis, the proteins 
were transferred to a nitrocellulose membrane 
(Schleicher & Schuell) using an ISS (integrated 
separation systems) Semidry Electroblotter 
(Daiichi Pure Chemicals Co. Ltd., Tokyo, Japan). 
The membrane was incubated with mouse anti-
human IV-C monoclonal antibody (clone 4H12) 
(Fuji Chemical Ind. Ltd., Toyama, Japan), and 
then with HRP-conjugated rabbit anti-mouse IgG, 
as described previously40). Immunoreactive pro-
tein bands were visualized by staining with 0.28 
mM 3,3'-diaminobenzidine (Dojindo Lab., Kuma-
moto, Japan) and 1.63 mM H202. Finally, the 
staining pattern of collagenous proteins was 
intensified by the Gold-Sulphide-Silver(GOSS) 
method of Iida et al21). 
Statistical analysis 
Statistical analyses were performed using Stat 
view (Abacus Concepts Inc., CA, USA) statistical 
software on an Apple Macintosh Ilci computer 
(Apple computer Inc., Cupertino, CA, USA). All 
data are presented as mean± SEM unless speci-
fied otherwise. Analysis of variance CANOVA) was 
performed to compare multiple groups. When re-
sults were statistically significant by ANOVA, the 
significance of differences between any two 
groups was determined by two-tailed Student's t-
test. A probability of p<0.05 was considered as 
statistically significant. Relationships between 
variables were assessed by Spearman rank cor-
relation or by linear regression analysis. 
RESULTS 
The clinical characteristics of the diabetic pa-
tients studied are shown in Table 1. The four pa-
tient groups did not differ significantly in age, 
duration of diabetes or BMI. Compared with the 
normoalbuminuric patients, patients with micro-
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Table 1. Clinical characteristics of the diabetic patients studied 
Diabetic patient groups 
N ormoalbuminuria Microalbuminuria Albuminuria Renal insufficiency 
n (M/F) 39 (12/27) 26 (13/13) 12 (4/8) 5 (2/3) 
NIDDM/IDDM (n) 30/9 22/4 12/0 5/0 
Age (year) 49±14 56±13 58±12 61±1 
Known duration of diabetes 15±10 18±7 18±5 17±9 (year) 
BMI (kg/m2) 22.0±3.2 22.1±3.0 21.9±3.3 24.1±1.7 
Prevalence of retinopathy 39/20/41 8/30/62 0/25/75 0/0/100 (%)* 
Antidiabetic treatment (%)'1l 18/18/49/15 4/19/69/8 8/25/59/8 20/0/60/20 
Systolic BP (mmHg) 132± 19 135±20 156±24b,g 178±22a,f 
Diastolic BP (mmHg) 78±11 76±10 89± 10c,g 94±4c,f 
Fasting blood glucose (mg/dl) 160±41 171±52 146±43 116± 18c,h 
HbAlc (%) 8.5± 1.6 8.6±1.7 7.5±2.0 7.0±1.7d 
Serum creatinine (mg/dl) 0.70±0.20 0.70±0.21 1.19 ± 0 .40a,e 3.50±1.0la,e,i 
Urinary albumin (mg/L) 9.7±6.9 83.7±89.7a 495.9 ± 284.6a,e 653.2± 167.7a,e 
Data given as mean± SD if not otherwise indicated. BP, blood pressure; BMI, body mass index. 
* Retinopathy is shown as normal retina/background retinopathy/proliferative retinopathy. 
'll Antidiabetic treatment is shown as diet only/oral hypoglycemic agents/insulin/oral hypoglycemic agents+ insulin. 
a p<0.0001, b p<0.001, c p<0.01, d p<0.05 vs nomoalbuminuria. e p<0.0001, f p<0.001, g p<0.01, h p<0.05 vs microalbu-
minuria. i p<0.0001 vs albuminuria. 
albuminuria, albuminuria and renal insufficiency 
had a higher prevalence of background or prolif-
erative retinopathy and were more often on insu-
lin therapy. The albuminuric patients and 
patients with renal insufficiency had significantly 
higher systolic and diastolic BP (sBP, dBP) 
compared with the normo- and microalbuminuric 
groups. No significant differences were found in 
fasting blood glucose and HbAlC levels among 
the normoalbuminuric, microalbuminuric and al-
buminuric groups, but these values were some-
what lower in the patients with renal 
insufficiency (p<0.05). 
Serum and urinary IV-C levels were significant-
ly elevated in diabetic patients with microangio-
pathy compared with control subjects (138.8 ± 4.5 
vs 85.0 ± 2.8µg!L, p<0.0001 and 77.8 ± 5.4 vs 
21.4 ± 2. 7 µg/L, p<0.0001, respectively) and even 
in those without clinical evidence of microangio-
pathy (97.2±5.0 vs 85.0±2.8 µg!L, p<0.05 and 
33.8±3.3 vs 21.4±2.7 µg!L, p<0.01, respectively); 
the levels in diabetic patients showed no sex dif-
ference and did not correlate with BMI. 
Serum IV-C levels increased slightly with age in 
the diabetic patients and were significantly high-
er (p <0.01) in patients ~ 60 years old compared 
with <40; whereas in the control subjects serum 
IV-C levels were not correlated with age. Urinary 
IV-C levels in both the control and diabetic sub-
jects did not show any significant change with 
age. In diabetic patients with a known duration 
of diabetes of <5, 5-9, 10-14, 15-19 and ~20 
years, serum IV-C levels were 94.6 ± 7.3, 
137.9±16.4, 124.0 ± 8.6, 143.2 ± 7.0, 137.6 ± 7.0 
µg/L, and urinary IV-C levels were 34.3 ± 5.4, 
65.6±14.4, 61.9 ± 8.5, 62.2 ± 9.6, 92.6 ± 9.8 µg!L, 
respectively. By ANOVA, both serum and urinary 
IV-C showed statistically significant differences 
between these groups (p<0.05 and p<0.01, respec-
tively). 
Fig. 1 shows serum and urinary IV-C levels in 
the control subjects and in the four groups of dia-
betic patients. There were significantly higher 
levels of serum and urinary IV-C in normoalbu-
minuric diabetic patients (111. 7 ± 4.6 and 
44.5 ± 3.1 µg/L) compared with control subjects 
(85.0±2.8 and 21.4±2.7 µg/L). These levels fur-
ther increased in patients with microalbuminuria 
(136.9±7.0 and 70.9±6.7 µg/L), albuminuria 
(166.7 ± 9.6 and 113.0±11.5 µg/L) and renal in-
sufficiency (163.5±15.6 and 156.8±19.1 µg/L) 
compared to those with normoalbuminuria; ANO-
VA confirmed significant differences between 
these groups (serum and urinary IV-C, both 
p<0.0001). The small number of IDDM patients 
were found only in the normo- and microalbu-
minuric groups, and their serum and urinary 
IV-C levels did not differ significantly compared 
with the respective groups of NIDDM patients 
(data not shown). Even in normo- and microalbu-
minuric patients, linear regression analysis dem-
onstrated significant positive correlation between 
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Fig. 1. Serum (-) and urinary ( ~) IV-C levels 
in control subjects and diabetic patients with dif-
ferent degrees of nephropathy. Values are 
mean± SEM. §p<0.0001, control subjects vs all four 
groups of diabetic patients; ***p<0.0001, normoal-
buminuria vs all other groups of diabetic patients; 
*p<0.005 and **p<0.001, normoalbuminuria vs mi-
croalbuminuria and albuminuria respectively; 
#p<0.05, microalbuminuria vs albuminuria; 
##p<0.001, microalbuminuria vs albuminuria and 
albuminuria vs renal insufficiency. 
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Fig. 2. Relationship between urinary IV-C and al-
bumin levels in normo- and microalbuminuric dia-
betic patients. A logarithmic transformation was 
used to normalise the distribution of urinary albu-
min and IV-C data. The solid line indicates linear 
regression and dotted lines represent the upper 
limit of normal for urinary albumin (log trans-
formed value 1.48) and for microalbuminuria (log 
transformed value 2.48). 
urinary IV-C and albumin levels (r = 0.55, 
p<0.0001; Fig. 2). In those patients with ACI <15, 
16-30, 31-90, 91-150 and 151-300 mg/g, urinary 
IV-C levels were also found to be proportionately 
elevated (p<0.001, ANOVA); however, using lin-
ear regression and the same ACI groupings, no 
correlation was noted between the serum IV-C 
and urinary albumin levels. 
When the four diabetic patient groups were 
considered together, serum and urinary IV-C 
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Fig. 3. Serum levels of IV-C in normoalbuminuric 
diabetic patients with different grades of retinopa-
thy compared with those without retinopathy. Hori-
zontal lines represent mean values. NS, not signifi-
cant; **p<0.001, no retinopathy vs proliferative re-
tinopathy; *p<0.05, background retinopathy vs pro-
liferative retinopathy. 
showed significant elevations as the degree of re-
tinopathy progressed from background to prolifer-
ative stages (p<0.01 and p<0.05, respectively by 
ANOVA). This observation remained statistically 
significant only for serum IV-C even in normoal-
buminuric patients (Fig. 3). 
Table 2 shows that the serum and urinary IV-C 
levels were not influenced by either blood glucose 
or HbAlC levels. Improved glycemic control, as 
indicated by a decrease in mean fasting blood 
glucose from 231.5±14.8 mg/dl to 124.7 ± 7.9 mg/ 
dl and mean HbAlC from 9.8 ± 0.3% to 6.8 ± 0.3% 
during 8 weeks of follow-up, did not alter the lev-
els of serum and urinary IV-C (Fig. 4). Further-
more, there was no relationship between the type 
of antidiabetic treatment and serum or urinary 
IV-C levels. 
Table 2, which represents the associations of se-
rum and urinary IV-C levels with other variables 
in the diabetic patients taken as a whole, shows 
that both serum and urinary IV-C levels were sig-
nificantly correlated with sBP, and urinary IV-C 
also with dBP. There was no correlation of serum 
and urinary IV-C levels with fasting serum cho-
lesterol level, but there was a significant correla-
tion between serum IV-C and fasting serum 
triglyceride levels. Serum and urinary IV-C were 
significantly correlated with serum creatinine. 
However, in patients with nephropathy (all pa-
tients apart from those with normoalbuminuria) 
serum IV-C did not show any intimate relation-
ship with serum creatinine, serum /32-microglobu-
lin or creatinine clearance; though in these 
patients correlations between urinary IV-C and 
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Fig. 4. Serum IV-C (a) and urinary IV-C (b) levels in the 12 diabetic patients before and after improve-
. ment of glycemic control, during 8 weeks of follow-up. Urinary IV-C levels (µg/L) are expressed in 
relation to creatinine (g/L) to exclude the influence of urine volume, as measured in first void early 
· morning urine samples. NS, not significant. 
Table 2. Association of serum and urinary IV-C levels with other variables, assessed by Spearman rank correlation 
Serum IV-C Urinary IV-C 
HbAlc (%) 
Fasting blood glucose (mg/dl) 
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Fasting serum cholesterol (mg/dl) 
Fasting serum triglyceride (mg/dl) 
Serum creatinine (mg/dl) 
BP, blood pressure; NS, not significant. 
Correlation 
coefficient 
-0.19 
-0.09 
0.30 
0.22 
0.24 
0.37 
0.35 
these parameters of renal function were present 
(data not shown). The urinary IV-C level did not 
show any significant association with the serum 
IV-C level in patients with or without nephropa-
thy. 
Taken as a whole, NDRD patients had signifi-
cantly elevated serum and urinary IV-C levels 
compared with control subjects (113.2 ± 8.6 vs 
85.0 ± 2.8 µg!L, p<0.01 and 115.5±10.8 vs 
21.4±2.7 µg/L, p<0.0001, respectively). Table 3 
demonstrates the serum and urinary IV-C levels 
in various types of NDRD. Although these levels 
were apparently higher in IgA nephropathy and 
lupus nephritis than in other NDRD groups, sta-
tistical significance was not achieved on account 
of the very small group sizes. In these patients, 
neither serum nor urinary IV-C levels showed 
any significant correlation with serum creatinine 
and creatinine clearance values. In NDRD pa-
tients, unlike diabetic patients, there was no cor-
p value Correlation p value 
coefficient 
NS -0.2 NS 
NS -0.2 NS 
<0.01 0.30 <0.01 
NS 0.26 <0.05 
NS 0.17 NS 
<0.01 0.25 NS 
<0.005 0.32 <0.005 
relation between urinary IV-C and albumin 
levels. 
There was a significantly lower level of serum 
IV-C in proteinuric NDRD patients compared 
with albumin uric diabetic patients (with and 
without renal insufficiency) (113.2 ± 8.6 vs 
165.7 ± 7.9 µg!L, p<0.005), whereas there was no 
significant difference in urinary IV-C levels be-
tween these two groups (Fig. 5a & 5b). However, 
the ratio of urinary IV-C to albumin was signifi-
cantly lower in proteinuric NDRD patients than 
in albuminuric diabetic patients, even after ad-
justing for serum creatinine and creatinine clear-
ance (120 ± 20 vs 310 ± 50, p<0.0001) (Fig. 5c). 
Fig. 6 shows the results of Western blotting un-
der reducing condition. The immunoreaction of 
the blotted antigen with a monoclonal antibody 
(clone 4H12) which was used in the IV-C assay 
system, revealed a single band of a(IV) monomer 
in both serum and urine, corresponding to a mo-
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Table 3. Serum and urinary IV-C levels in various types of non-diabetic renal diseases 
Serum creatinine Serum IV-C Urinary albumin Urinary IV-C 
(mg/dl) (µg/L) (g/L) (µg/L) 
Minimal change GN (nephrotic phase) 0.71±0.09 92.7±20.0 2.5± 1.2 72.9± 15.5 (n=3) 
Mesangial proliferative GN 4.59± 1.20 122.5±20.3 1.6±0.5 121.8± 13.2 (IgA nephropathy) (n=ll) 
Non IgA mesangial proliferative GN (n=5) 1.10 ± 0.20 117.5±23.8 1.5±0.7 112.1±28.9 
Membranous GN (n=6) 1.80± 1.01 90.8± 11.9 1.6±0.4 95.6±29.2 
Mesangiocapillary GN (n=l) 0.93 144.4 1.0 58.5 
Sclerosing GN (n=2) 5.19±2.01 119.9±42.3 2.8± 1.9 112.4±.30.4 
Lupus nephritis (n=3) 0.90±0.20 142.7±21.7 1.4±0.4 218.6±48.3 
Amyloidosis (n=l) 6.79 72.7 0.27 81.9 
All values given as mean± SEM. GN, glomerulonephritis. 
a. b. c. 
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Fig. 5. Serum IV-C (a), urinary IV-C (b) levels, and the urinary IV-CI albumin ratio (c) in proteinuric 
NDRD patients compared with albuminuric diabetic patients. In (a) and (b) results are mean±SEM. In 
(c) ratios are shown after adjusting serum creatinine and creatinine clearance values of two patient 
groups. NS, not significant; *p<0.005 and **p<0.0001, albuminuric diabetic patients vs proteinuric 
NDRD patients. 
lecular mass of approximately 140 kDa. Serum· 
and urinary a(IV) monomeric fragments in dia-
betic and NDRD patients had a similar mobility 
to calibrator human placental IV-C. 
DISCUSSION 
A number of recent studies have demonstrated 
elevated levels of 78 collagen and type IV colla-
gen in the serum of diabetic patients with micro-
angiopathy and a significant difference in its 
concentration between those with and without 
microangiopathy2o,33,46). Although the NCl do-
main of type IV collagen has been found to be 
elevated in the serum of streptozotocin-diabetic 
rats3), some studies have shown no rise in serum 
NCl levels in diabetic nephropathy and vasculo-
pathy13·47)_ Torffvit et al47), who demonstrated in-
creased urinary NCl excretion in IDDM patients 
in incipient diabetic nephropathy, could not de-
tect any rise in serum NCl in the same patients. 
Although the results of most previous studies 
have been similar to those found here, the source 
of some of the variation was probably due to the 
use of different radioimmunochemical methods 
for the measurement of IV-C and its fragments. 
The one-step sandwich EIA method used in the 
present study is highly sensitive and specific for 
the detection of this antigen in serum32·34). The 
sensitivity of the assay, which was not sufficient 
for detection of IV-C in original whole urine ex-
cept in a few cases of advanced diabetic nephro-
pathy33), was increased in this study by 
PEG-based 100-fold concentration of urine, which 
showed good recovery and reproducibility for the 
measurement of urinary IV-C in our previous 
study1). 
In this study, serum and urinary concentrations 
of IV-C were measured at different stages of dia-
betic microangiopathy, particularly nephropathy, 
and were compared with measurements in pa-
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Fig. 6. Western blotting of immunoprecipitate from 
calibrator human placental IV-C (lane 1), serum 
and PEG-concentrated urine samples of a patient 
with diabetic nephropathy (lanes 2 & 3, respective-
ly) and non-diabetic renal disease (lanes 4 & 5, re-
spectively). 
Molecular weight standards are shown in kilodal-
tons. 
tients with various non-diabetic renal diseases. 
Both serum and urinary IV-C levels were dis-
tinctly elevated even in diabetic patients without 
clinical evidence of microangiopathy, compared 
with control subjects, and the degree of elevation 
increased with progression of nephropathy and 
retinopathy. These observations confirmed our 
speculation that determination of serum and uri-
nary IV-C levels in diabetic patients may be im-
portant in the early detection and follow-up of 
the progression of microangiopathy. 
The significant correlations of urinary IV-C lev-
el with the level of urinary albumin and various 
parameters of renal function such as serum 
creatinine and creatinine clearance values indi-
cate that elevation of urinary IV-C level is 
associated with progression of diabetic nephropa-
thy. Moreover, the elevated urinary IV-C levels 
found even in normoalbuminuric diabetic pa-
tients, and its proportionate rise with increase in 
ACI in normo- and microalbuminuric diabetic pa-
tients, indicate that urinary IV-C concentrations 
may also be a useful indicator of incipient renal 
damage. Although a significant relationship was 
found between urinary IV-C levels and progres-
sion of retinopathy in the diabetic population of 
this study, this observation may however be the 
effect of concurrent nephropathy in patients with 
advanced retinopathy, since the patients with 
clinical evidence of nephropathy had a higher 
prevalence of proliferative retinopathy (Table 1), 
and a previous study reported a higher concor-
dance rate between renal and retinal lesions in 
diabetic patients with advanced retinopathy8). On 
the other hand, the raised serum IV-C found in 
association with the progression of retinopathy 
even in normoalbuminuric patients indicates that 
not only the progression of nephropathy but also 
of retinopathy might have an influence on serum 
IV-C levels. 
In a recent study (a report in abstract form, in 
Diabetes 40: 263A, 1991), Matsumoto et al found 
a weak negative correlation between fructosa-
mine and serum IV-C levels; this was thought to 
be the result of suppressed biosynthesis of IV-C 
in poorly controlled patients. In our study, gly-
cemic control as assessed by HbAlC did not corre-
late with either serum or urinary IV-C levels. 
This is consistent with the findings of Tomono et 
al46). Furthermore, the absence of changes in se-
rum and urinary IV-C levels with improvement of 
glycemic control during 8 weeks of follow-up sug-
gests that short term changes in glycemic control 
have no effect on serum and urinary IV-C levels. 
In the present study, albuminuric diabetic pa-
tients with or without renal insufficiency had sig-
nificantly higher sBP and dBP compared with 
normo- and microalbuminuric patients. The sig-
nificant correlations observed between IV-C levels 
and BP may therefore partly be attributable to 
hypertension, which was present in association 
with diabetic nephropathy. Previous studies have 
demonstrated raised serum triglyceride levels in 
diabetic patients with nephropathy6) and a major 
association between urinary albumin excretion 
and fasting serum triglycerides ll). In our study, 
we observed similar results (data not shown). 
However, urinary IV-C levels which were raised 
proportionately to the degree of progression of 
diabetic nephropathy, and which were significant-
ly correlated with urinary albumin levels, did not 
show any association with serum triglycerides; 
whereas we found a significant association be-
tween serum IV-C and triglycerides. The signifi-
cance of this observation is therefore uncertain. 
The four groups of diabetic patients studied 
here did not differ significantly in the duration of 
diabetes; however, an increased prevalence of mi-
crovascular complications was found with the in-
crease in length of duration. A significant rise in 
serum and urinary IV-C levels found after 5 
years of the onset of diabetes may be the result 
of the increased incidence or prevalence and se-
verity of diabetic microangiopathy associated 
with increased length of duration. Higher serum 
IV-C concentrations found in diabetic patients of 
~ 60 years of age compared with those of <40 
years of age may also be the effect of diabetic 
microangiopathy, because the older patients had 
a higher prevalence of microangiopathy. Although 
the control subjects did not show any correlation 
between age and serum IV-C concentration, the 
possibility of a significant age effect can not be 
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excluded because subjects under 40 were not stu-
died. 
Recently, using the technique of molecular siev-
ing chromatography, we have found that sand-
wich EIA detects a single peak of >500,000 Mr 
IV-C in PEG-concentrated urine1>. Using the 
same method, a previous study also demonstrated 
a high molecular weight IV-C in serum32). In the 
present study, immunoblotting with a monoclonal 
antibody, which was used in the IV-C assay sys-
tem, revealed that serum and urinary IV-C in 
diabetic and NDRD patients has a high molecular 
weight similar to human placental IV-C. These 
results indicate that serum and urinary IV-C, 
measured by sandwich EIA, is a whole molecule 
and not a degradation product of pre-existing 
IV-C. Measurement of IV-C levels by EIA prob-
ably reflects their increased synthesis or de-
creased degradation. Several recent in vivo and 
in vitro studies have suggested that the increased 
IV-C accumulation in glomerular and tubular 
basement membranes, and in mesangial matrix 
found in diabetic nephropathy, is due to increased 
synthesis5·9·12·18•29·36·37·50) or decreased degrada-
tion10·39). 
Elevated serum IV-C levels in diabetic patients 
are probably not caused by impaired renal excre-
tion, because they did not correlate with serum 
creatinine or creatinine clearance in patients 
with nephropathy. Furthermore, the finding of 
high serum IV-C levels even in normoalbuminuric 
patients excludes this possibility. Raised serum 
IV-C concentrations most likely originate from al-
tered basement membrane IV-C metabolism of 
various tissues involved in diabetic microangiopa-
thy. The origin of urinary IV-C in diabetic pa-
tients is unclear. Urinary IV-C is a high 
molecular weight protein. Nevertheless, elevated 
levels were found in patients with incipient neph-
ropathy and even in those without evidence of 
nephropathy who probably have a normal glom-
erular filtration barrier. Alterations of glomerular 
and tubular basement membrane metabolism 
rather than glomerular filtration dysfunction may 
be the origin of raised urinary IV-C in these pa-
tients. However, these patients showed a signifi-
cant correlation between urinary IV-C and 
albumin, so the possibility of increased glomeru-
lar filtration of IV-C in the early stage of nephro-
pathy cannot be excluded. In the advanced stage 
of diabetic nephropathy elevated urinary IV-C 
could, however, reflect a disorder of the glomeru-
lar filtration barrier together with altered glom-
erular and tubular basement membrane 
metabolism, although there was no correlation 
between serum and urinary IV-C in patients with 
clinical evidence of nephropathy. 
In the present study we found elevated serum 
and urinary IV-C levels in various NDRD, the 
levels differing according to the intrinsic type of 
renal disease. These findings are consistent with 
those of Keller et al26). In our study, the NDRD 
patients who were receiving our inpatient treat-
ment were included and could be considered to 
have active rather than chronic renal disease be-
cause they had either a deterioration of renal 
function or an indication for renal biopsy or were 
being treated with immunosuppressive agents. 
Furthermore, the NDRD patients studied here 
also had greater proteinuria and worse renal 
function than albuminuric diabetic patients. 
However, interestingly, the proteinuric NDRD pa-
tients as a whole had lower serum IV-C levels 
than the albuminuric diabetic patients. Further-
more, even after adjusting for serum creatinine 
and creatinine clearance, there was a significant 
difference in the urinary IV-C I albumin ratio be-
tween the proteinuric NDRD patients and albu-
minuric diabetic patients. In diabetic patients it 
is desirable to ascertain whether proteinuria re-
sults from diabetic or non-diabetic renal involve-
ment. However, this is a rather difficult task for 
a clinician, without histological findings of renal 
biopsy, particularly when diabetic patients are 
presented with albuminuria in the presence or 
absence of mild retinopathy together with a short 
medical history of NIDDM. The findings of our 
study suggest that a low serum IV-C level togeth-
er with a low urinary IV-C I albumin ratio in 
these diabetic cases may indicate the presence of 
NDRD rather than diabetic nephropathy. In 
NDRD patients elevated serum IV-C most likely 
originates from the kidney, whereas in diabetic 
patients with nephropathy it probably originates 
from the basement membranes of various tissues 
involved in microangiopathy rather than from the 
kidney alone. This may explain the lower level of 
serum IV-C in NDRD patients. In NDRD patients 
urinary IV-C level was independent of renal func-
tion, whereas in albuminuric diabetic patients it 
was associated with deteriorating renal function. 
We conclude that the measurement of serum 
and urinary IV-C concentrations may be a useful 
new marker for monitoring the development and 
progression of diabetic microangiopathy, particu-
larly nephropathy. From the results of the pres-
ent study, urinary IV-C appears to be a more 
sensitive marker of early diabetic nephropathy 
than serum IV-C. Assessment of the degree of al-
teration in glomerular extracellular matrices and 
tubular basement membrane in diabetic patients 
may also be possible by measuring urinary IV-C. 
In addition, determination of the serum IV-C and 
urinary IV-C I albumin ratio may allow diabetic 
nephropathy and non-diabetic renal disease to be 
differentiated. 
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